ALCL anaplastic large cell lymphoma, ALK anaplastic lymphoma kinase, AXL tyrosine-protein kinase receptor UFO, c-MET hepatocyte growth factor receptor, EMA European Medicines Agency, FDA US Food and Drug Administration, FLT-3 fms like tyrosine kinase 3, KIT KIT proto-oncogene receptor tyrosine kinase, MTC medullary thyroid cancer, NSCLC non-small cell lung cancer, RCC renal cell carcinoma, RET REarranged during Transfection, ROS1 ROS proto-oncogene 1, TIE-2 tyrosine-protein kinase receptor TIE-2, TKI tyrosine kinase inhibitor, TRKB tyrosine receptor kinase B, VEGF vascular endothelial growth factor, VEGFR vascular endothelial growth factor receptor a ALK -fusion positive and ROS1 -positive NSCLC as detected by an FDA-approved test In this review, we will present an overview of approved and novel promising c-MET-inhibitors, with a focus on their safety profile and tolerability
10.1186/s12891-025-08539-6 103 IannittiT.LodiD.PalmieriB
This happens faster at higher temperatures and at extreme pH levels
These dosage recommendations are not definitive and should be adjusted based on research context and medical guidance
2G), in agreement with genetic studies in murine models 31
